DK1054680T3 - Behandling af blærecancer med mycobacterium phlei cellevæg - Google Patents

Behandling af blærecancer med mycobacterium phlei cellevæg

Info

Publication number
DK1054680T3
DK1054680T3 DK98962163T DK98962163T DK1054680T3 DK 1054680 T3 DK1054680 T3 DK 1054680T3 DK 98962163 T DK98962163 T DK 98962163T DK 98962163 T DK98962163 T DK 98962163T DK 1054680 T3 DK1054680 T3 DK 1054680T3
Authority
DK
Denmark
Prior art keywords
cell wall
treatment
phlei
bladder cancer
phlei cell
Prior art date
Application number
DK98962163T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of DK1054680T3 publication Critical patent/DK1054680T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98962163T 1998-02-18 1998-12-22 Behandling af blærecancer med mycobacterium phlei cellevæg DK1054680T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7511198P 1998-02-18 1998-02-18
PCT/CA1998/001190 WO1999042113A1 (en) 1998-02-18 1998-12-22 Composition and method for the treatment of bladder cancer
EP98962163A EP1054680B1 (en) 1998-02-18 1998-12-22 Treatment of bladder cancer by mycobacterium phlei cell wall

Publications (1)

Publication Number Publication Date
DK1054680T3 true DK1054680T3 (da) 2005-06-27

Family

ID=22123625

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98962163T DK1054680T3 (da) 1998-02-18 1998-12-22 Behandling af blærecancer med mycobacterium phlei cellevæg

Country Status (13)

Country Link
EP (1) EP1054680B1 (da)
JP (1) JP4426097B2 (da)
CN (1) CN1153576C (da)
AT (1) ATE290390T1 (da)
AU (1) AU751667B2 (da)
CA (1) CA2321296A1 (da)
DE (1) DE69829316T2 (da)
DK (1) DK1054680T3 (da)
ES (1) ES2238780T3 (da)
NZ (1) NZ506406A (da)
PT (1) PT1054680E (da)
RO (1) RO122992B1 (da)
WO (1) WO1999042113A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541264A (ja) 1999-04-08 2002-12-03 ユーエイビー・リサーチ・ファウンデーション 冨gオリゴヌクレオチドの抗増殖活性およびヌクレオリンに結合するためのその使用方法
AU7501700A (en) * 1999-09-29 2001-04-30 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CA2395493C (en) 1999-12-28 2010-06-22 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
CN101829154B (zh) * 2010-04-23 2012-12-26 广西医科大学第一附属医院 防治哮喘的药物组合物的制备方法
CN105943559A (zh) 2010-10-13 2016-09-21 特莱斯塔治疗知识产权公司 细菌核糖核酸细胞壁组合物及其制备和使用方法
TR201101874A2 (tr) 2011-02-25 2011-08-22 Leyla A�An Nac�Ye Yüzeyel mesane tümorü tedavisinde kullanılabilecek mycobacterıum(mikobakteri) brumae hücre duvarı ekstreleri.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) * 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
NZ506406A (en) 2002-11-26
HK1030887A1 (en) 2001-05-25
CN1290171A (zh) 2001-04-04
ES2238780T3 (es) 2005-09-01
CA2321296A1 (en) 1999-08-26
JP2002503697A (ja) 2002-02-05
PT1054680E (pt) 2005-06-30
EP1054680B1 (en) 2005-03-09
ATE290390T1 (de) 2005-03-15
DE69829316T2 (de) 2006-04-13
RO122992B1 (ro) 2010-06-30
AU1746599A (en) 1999-09-06
JP4426097B2 (ja) 2010-03-03
DE69829316D1 (de) 2005-04-14
WO1999042113A1 (en) 1999-08-26
CN1153576C (zh) 2004-06-16
AU751667B2 (en) 2002-08-22
EP1054680A1 (en) 2000-11-29

Similar Documents

Publication Publication Date Title
DK0762898T3 (da) Cyclodextrinsystem til levering af oligonukleotider til celler
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
CA2291065A1 (en) Raf kinase inhibitors
PT1242060E (pt) Tratamento da doenca metastatica
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
RU96102402A (ru) Композиция для фотодинамического повреждения клеток-мишеней и способ фотодинамического повреждения клеток-мишеней
DK1054680T3 (da) Behandling af blærecancer med mycobacterium phlei cellevæg
WO2001006990A3 (en) Use of etodolac to treat cancer
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
SI1147103T1 (en) Phenantrhridine-n-oxides with pde-iv inhibiting activity
DE60033918D1 (de) Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung
MY121046A (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
PT1147087E (pt) Feantridina-n-oxidos com actividade de inibicao de pde-iv
DK1147088T3 (da) 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet
TR200102837T2 (tr) ídrar tutamama durumunun tedavisi
HUP9904669A2 (hu) A T-BAM(CD40L)technológia terápiás alkalmazása simaizomsejtekkel kapcsolatos betegségek kezelésére
TR200001941T1 (tr) TNF ve PDE-IV önleyici aktiviteye sahip heterosiklik bileşiklerin N-oksitleri.
EP1165106B8 (en) Composition and method for inducing apoptosis in prostate cancer cells by m-dna and mcc
DE69734690D1 (de) Monoklonaler Antikörper gegen Fibroblasten-Wachstumsfaktor-8
DE69919386D1 (de) Zusammensetzung zur behandlung von entzündungen
RU98109220A (ru) Способ лечения экземы
PT1135161E (pt) Composicao e metodo terapeutico
WO2002060455A8 (en) Methods and compositions utilizing 2'-5' oligoadenylates in the treatment of disorders of cell proliferation